Veterinary Clinical Reference
Look up any drug or condition.
Evergreen, evidence-based hubs on the drugs, conditions, and species you manage — continuously updated and cited at every claim.
Buspirone for Cats: Urine Spraying, Anxiety, and Off-Label Use in Feline Behavioral Medicine
Buspirone is a non-sedating azapirone (5-HT1A partial agonist) used off-label in cats, best supported for urine spraying/marking in multi-cat households and for generalized, social, and fear-based anxiety. Onset is 1–4 weeks, so it is a maintenance adjunct — not a rescue for acute situational anxiety.
Read →Lily Nephrotoxicosis in Cats: AKI Emergency Reference
Any true-lily (Lilium or Hemerocallis) exposure in a cat is a nephrotoxic emergency — pollen and vase water included. Clinician reference on the unidentified toxin, proximal tubular necrosis, the biphasic timeline, early glucosuria, aggressive IV fluid diuresis, and the ~18-hour therapeutic window.
Read →Permethrin Toxicosis in Cats: Clinical Management
A clinician's reference on feline permethrin toxicosis: why cats are uniquely susceptible, the tremor-and-seizure presentation, and the supportive protocol—decontamination, methocarbamol, ILE, and thermoregulation—that gives most cats an excellent prognosis.
Read →Feline Herpesvirus (FHV-1) Keratitis: Antivirals and Steroid Caution
A clinical hub on FHV-1 ocular disease for practicing vets: recognizing dendritic ulcers, stromal and eosinophilic keratitis, and symblepharon; interpreting PCR; dosing oral famciclovir and topical cidofovir/idoxuridine; the settled L-lysine question; and the corticosteroid caution in active epithelial disease.
Read →Feline Ocular FIP and Anterior Uveitis: GS-441524 Treatment
Ocular FIP is a treatable pyogranulomatous panuveitis, not a death sentence. A practical hub on diagnosis, GS-441524/remdesivir dosing and ocular penetration, adjunct topical care, IOP monitoring, and prognosis for the practicing veterinarian.
Read →Feline Hypertrophic Cardiomyopathy: ACVIM Staging, Diagnosis, and Evidence-Based Management
A clinician-facing evidence hub on feline HCM: ACVIM 2020 staging, echocardiographic diagnosis, clopidogrel-based thromboprophylaxis with the FAT CAT trial and its 2024 absolute-benefit re-analysis, acute FATE management, and emerging myosin-inhibitor and rapamycin therapies.
Read →Methimazole and Carbimazole for Feline Hyperthyroidism: Pharmacology, Dosing, and Adverse Effect Management
Methimazole 1.25-2.5 mg PO BID is the standard medical therapy for feline hyperthyroidism, controlling but not curing disease. This hub consolidates dosing, adverse-effect management, carbimazole and transdermal options, and how medical management compares with radioiodine, iodine-restricted diet, and surgery — including the concurrent-CKD reversibility trial.
Read →Velagliflozin (Senvelgo) for Feline Diabetes Mellitus: SGLT2 Inhibition, Efficacy and Safety
Velagliflozin (Senvelgo) is a once-daily oral SGLT2 inhibitor for the insulin-naive diabetic cat: the SENSATION trial (n=252) cut median blood glucose from 436 to 125 mg/dL by day 180. This hub covers efficacy, the euglycemic DKA hazard, mandatory BHB monitoring, patient selection, and how it compares with bexagliflozin and insulin.
Read →Robenacoxib for Feline Musculoskeletal Pain: COX-2 Selectivity, DJD Evidence, Safety, and the ISFM/AAFP Framework
The evergreen clinical hub on robenacoxib (Onsior) for feline musculoskeletal and DJD pain: COX-2 tissue selectivity and PK, the Adrian 2021 pilot RCT (49% disability reduction, NNT 3.8), King 2021 pooled chronic safety with a CKD subgroup, grapiprant comparator and NSAID-timing data, and the 2024 ISFM/AAFP monitoring framework.
Read →Robenacoxib (Onsior) for Pain in Cats and Dogs: COX-2 Selectivity and Clinical Evidence
Robenacoxib (Onsior) is a COX-2-selective NSAID with tissue-preferential distribution. Evidence from a feline DJD RCT and perioperative comparison data reviewed.
Read →Rapamycin (Sirolimus) for Feline Hypertrophic Cardiomyopathy: RAPACAT Trial, Evidence, and Safety
The RAPACAT RCT showed low-dose delayed-release rapamycin significantly reduced LV wall-thickness progression in subclinical feline HCM at Day 180 (P=0.01), with mechanistic and ex vivo platelet-safety data now folded into one evergreen clinical reference.
Read →Cyclosporine (Atopica for Cats) for Feline Allergic Dermatitis: Efficacy and Safety
Atopica for Cats produced a 65.1% lesion score reduction vs 9.2% in controls in a 181-cat field study. FDA-indicated for miliary dermatitis, eosinophilic plaques, excoriations, and self-induced alopecia.
Read →